Bugatinib is an oral inhibitor of receptor tyrosine kinase asexual lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), with potential anti-tumor activity. Bugatinib binds and inhibits ALK kinase and ALK fusion protein, as well as EGFR and mutants. This leads to inhibition of ALK kinase and EGFR kinase, disrupting their signaling pathways and ultimately inhibiting the growth of susceptible tumor cells. In addition, AP26113 seems to be able to overcome mutation based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in the development of the nervous system; ALK dysregulation and gene rearrangement are associated with a range of tumors. EGFR is overexpressed in various types of cancer cells.